Urogen Pharma $URGN Shares Bought by Vestal Point Capital LP

Key Points

• Vestal Point Capital LP increased its stake in Urogen Pharma by 32.1%, now holding approximately 2.15 million shares valued at $23.81 million, constituting 1.7% of its portfolio.
• Urogen Pharma reported a loss of ($1.05) earnings per share in its latest quarter, missing expectations, despite generating $24.22 million in revenue.
• Analysts are optimistic, with Guggenheim and Piper Sandler setting new price targets at $30.00 and $36.00, respectively, and a consensus target price of $32.00 for the stock.

Vestal Point Capital LP boosted its position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 32.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,152,957 shares of the company's stock after purchasing an additional 522,957 shares during the quarter. Urogen Pharma makes up 1.7% of Vestal Point Capital LP's portfolio, making the stock its 20th biggest holding. Vestal Point Capital LP owned 4.67% of Urogen Pharma worth $23,812,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. CWM LLC raised its stake in shares of Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after buying an additional 5,140 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Urogen Pharma during the fourth quarter worth about $67,000. GAMMA Investing LLC lifted its holdings in shares of Urogen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after purchasing an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $101,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $137,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Insider Activity at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 7,522 shares of Urogen Pharma stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the sale, the general counsel owned 41,492 shares in the company, valued at $794,156.88. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Schoenberg sold 10,000 shares of the company's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the transaction, the insider owned 148,229 shares of the company's stock, valued at $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,833 shares of company stock valued at $457,467 in the last ninety days. 4.70% of the stock is owned by corporate insiders.

Urogen Pharma Trading Up 0.4%

URGN traded up $0.08 during trading on Friday, hitting $18.88. 1,029,077 shares of the company's stock were exchanged, compared to its average volume of 1,527,646. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $21.01. The stock has a 50 day moving average price of $17.54 and a 200 day moving average price of $12.52. The firm has a market cap of $873.39 million, a P/E ratio of -5.69 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The business had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Guggenheim reaffirmed a "buy" rating and issued a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Piper Sandler began coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They issued an "overweight" rating and a $36.00 target price for the company. HC Wainwright decreased their price target on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Finally, Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the company a "buy" rating in a research report on Friday, June 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $32.00.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.